Biogen Inc. (BIIB) Position Held by Maple Capital Management Inc

Biogen's spinal muscular atrophy treatment Spinraza was approved last December

Biogen's spinal muscular atrophy treatment Spinraza was approved last December

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, April 25th. Ibex Wealth Advisors bought a new stake in Biogen during the fourth quarter worth about $651,000. Chevy Chase Trust Holdings Inc. now owns 201,496 shares of the biotechnology company's stock worth $55,093,000 after buying an additional 4,354 shares during the last quarter. Beacon Trust Co. now owns 1,135 shares of the biotechnology company's stock worth $328,000 after buying an additional 6 shares during the last quarter. Rational Advisors LLC raised its stake in Biogen by 14.3% in the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company's stock worth $229,000 after buying an additional 6 shares during the period. Wetherby Asset Management reported 0.18% in Biogen Inc (NASDAQ:BIIB). Rosenbaum Jay D. now owns 1,704 shares of the biotechnology company's stock worth $466,000 after buying an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 87.50% of the company's stock. Finally, Carroll Financial Associates Inc. raised its position in Biogen by 1.2% in the second quarter. (BIIB) opened at 284.70 on Tuesday.

Its 52-week range quite noticeable, lower range was $7.16% and hit highest level of $-39.25%. In taking a look at the company's valuation, the firm's price to earnings ratio stands at 17.83.

In looking at where the stock is trading on a technical level, the stock is trading +5.12% away from its 50 day moving average of $270.82.

NASA's dreams of quiet supersonic jet closer to fruition
But aside from being years away commercially, the other downsides include the plane's high carbon emissions and noise pollution. It is expected start-ups such as Boom Technology and billionaire Robert Bass's Aerion will be quick to jump on the opportunity.

Biogen Inc. (NASDAQ:BIIB) cuts 2017 net EPS view to range of $17.05 to $17.65. The biotechnology company reported $5.04 EPS for the quarter, topping the consensus estimate of $4.50 by $0.54. Biogen Inc Q2 revenue $3.08 billion vs. $2.89 billion year ago. Biogen has also built up $30 million in inventory.

Spinraza could become one of the company's "largest commercial assets, shifting the center of gravity for Biogen beyond MS", CEO Michel Vounatsos said in a post-earnings conference call. During the same period past year, the business posted $5.21 EPS. First National Bank Of Hutchinson invested in 0.38% or 2,189 shares. Envestnet Asset Management Inc has invested 0.05% in Biogen Inc (NASDAQ:BIIB). More interesting news about Biogen Inc (NASDAQ:BIIB) were released by: Nasdaq.com and their article: "BUZZ-US STOCKS ON THE MOVE-Alphabet, Caterpillar, Biogen, Domino's Pizza" published on July 25, 2017 as well as Fool.com's news article titled: "How Biogen Inc". If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & global trademark & copyright law.

Several equities research analysts have commented on the company. Barclays PLC restated an "overweight" rating and set a $360.00 price objective (down from $380.00) on shares of Biogen in a research note on Sunday, April 23rd. Citigroup Inc. lifted their target price on Biogen from $305.00 to $315.00 and gave the stock a "buy" rating in a research note on Tuesday, April 4th. Cantor Fitzgerald reissued a "neutral" rating on shares of Biogen in a research report on Wednesday, March 29th. Thirteen equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. $340.20's average target is 19.30% above currents $285.17 stock price. The stock was acquired at an average price of $278.50 per share, with a total value of $20,569,453.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

British Open 2017: Branden Grace shoots first 62 in major history
Grace laid down the early challenge Saturday, setting the stage in balmy conditions compared with the gales and deluge of Friday. Zach Johnson, Justin Thomas and Rickie Fowler were among those who waited by the 18th to watch Spieth capture yet another major.

In other Biogen news, EVP Susan H. Alexander sold 7,758 shares of the firm's stock in a transaction that occurred on Wednesday, July 19th.

About 2.17M shares traded or 40.91% up from the average. Following the completion of the transaction, the director now directly owns 6,330 shares of the company's stock, valued at approximately $1,622,442.30. The disclosure for this purchase can be found here. The stock declined 0.67% or $1.91 reaching $282.79 on the news.

Biogen has done deals over the past year, but a number of analysts have complained that they haven't seen the company get down to business in earnest. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It worsened, as 90 investors sold BIIB shares while 341 reduced holdings.

Barrick Gold Corporation (NYSE:ABX) Receives An Update From Brokers
Be in Your Portfolio?" published on July 17, 2017, Fool.ca published: " Barrick Gold Corp.: "Buy or Sell?" on July 24, 2017. It dropped, as 66 investors sold CHK shares while 91 reduced holdings. 53 funds opened positions while 33 raised stakes.

Últimas notícias